Physician profile
Leroy Vickers
NPI 1578561866
$2,720.27
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $467 · 2021: $474 · 2022: $603 · 2023: $568 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.55 | 2019-2023 | Vraylar, Rinvoq, Ubrelvy |
| Novo Nordisk INC | $331.35 | 2019-2023 | |
| Pfizer INC. | $233.32 | 2019-2023 | |
| Abbott Laboratories | $227.89 | 2021-2024 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $184.89 | 2020-2023 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $156.18 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $145.67 | 2019-2020 | |
| Amgen INC. | $98.77 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $93.27 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $89.03 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $79.50 | 2021-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $71.85 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.27 | 2020-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $55.18 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.95 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $42.86 | 2019-2020 | |
| Allergan, INC. | $35.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.06 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $28.63 | 2022 | |
| Dexcom, INC. | $28.60 | 2021-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $28.10 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $26.04 | 2021 | |
| Eisai INC. | $24.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.05 | 2020 | |
| Dynavax Technologies Corporation | $21.09 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.85 | 2020 | |
| Oxford Immunotec USA INC | $20.55 | 2020 | |
| Exact Sciences Corporation | $19.70 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $19.65 | 2019 | |
| Phadia US INC. | $17.40 | 2022 | |
| Tactile Systems Technology INC | $13.13 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.69 | 2019 | |
| Esperion Therapeutics, INC. | $12.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.95 | 2022 | |
| Amarin Pharma, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.